BioDiscovery Research and Clinical Software

Adoption of the N_xClinical software has provided an efficient and secure workflow for our data batch loading and processing at our high volume clinical laboratory.

We were eager to be part of the Early Access program and try out N_xClinical 4.1 Beta. We have been using N_xClinical for many years and each release has features that we find really useful. BioDiscovery has also been very receptive to feedback from us on feature requests and we are happy to see many of those implemented in version 4.1 as they make our interpretation process even easier.

Nexus Copy Number is a powerful tool in our workflow, allowing direct visualization of data from numerous platforms, with a graphical interface that is as appealing as it is informative.

We have been using Nexus Copy Number and very happy with it. It allows direct visualization of data from different platforms with informative graphical interfaces. We integrated this powerful tool in our workflow.

My CAP/CLIA clinical lab has used BioDiscovery CNV software since 2012. I have evaluated many CNV analysis software programs and the BioDiscovery software always has been the best choice for my lab. I have watched the progression of their software development from Nexus Copy number to N_xClinical 4.1 and have always been satisfied with their improvements. BioDiscovery listens to their customers and utilizes this information to improve and refine their software for clinical laboratories. N_xClinical 4.1 continues to be intuitive to use, has a searchable database, and has new desirable features. I now use N_xClinical 4.1 to analyze CNV data from the CytoScan XON array. I am able to define gene panels and only analyze the genes from a targeted list. Also, I like that N_xClinical can be used to analyze NGS data to make CNV calls and I am in the process of evaluating this new feature.

At the UCSD clinical genetics lab, we are tasked with providing a complete and clinically actionable genomic profile of a patient's tumor. N_xClinical allows us to do this rapidly and comprehensively by allowing us to consider CNV, LOH, and sequence variants together within a single software. The combined analysis facilitates interpretation in particular with double hit events while allowing us to save resources. In addition, the ability of N_xClinical to call CNVs from NGS is an added bonus that will allow us to replace multiple assays with a single NGS assay for interrogation of all genomic variants.

The functionality of N_xClinical has allowed us to simplify and standardize our interpretation of CNVs across our group of Directors. This significantly reduces the time required to review the 10+ variants identified per genome.